Teduglutide

Teduglutide is the regulatory credibility flagship for gastrointestinal peptide pharmacology — the only FDA-approved peptide on this site where the indication is driven primarily by mucosal-growth pharmacology rather than the metabolic or hormonal mechanisms that anchor the GLP-1 class and the GH-axis class. The approval rests on a tight trial chronology in short bowel syndrome (SBS), a malabsorption condition in which extensive intestinal resection (often for Crohn's disease, mesenteric ischemia, or congenital anomalies) leaves patients dependent on parenteral support for fluid, electrolyte, and caloric needs. The pivotal trial is Jeppesen, Pertkiewicz, Messing et al., Gastroenterology 2012, 143:1473–1481.e3 — the STEPS trial — a Phase III, multicenter, randomized, double-blind, placebo-controlled study that enrolled 86 SBS-intestinal-failure patients on stable parenteral support and randomized them 1:1 to teduglutide 0.05 mg/kg/day subcutaneously versus placebo for 24 weeks. The primary endpoint of a 20–100% reduction in weekly parenteral support volume at weeks 20 and 24 was met by 27 of 43 teduglutide patients (63%) versus 13 of 43 placebo patients (30%; p=0.002). Mean parenteral support reduction was 4.4 L/week on teduglutide versus 2.3 L/week on placebo, with the effect propagating through villous height, plasma citrulline (an enterocyte mass biomarker), and reduced infusion days per week.

The long-term extension is Schwartz LK, O'Keefe SJ, Fujioka K et al., Clin Transl Gastroenterol 2016, 7:e142 — STEPS-2 — a 2-year open-label continuation that enrolled 88 patients from STEPS-1 (whether they had received teduglutide or placebo originally) plus six patients who qualified for STEPS-1 but were not treated due to full enrollment. Of the 65 patients who completed STEPS-2, 28 of 30 (93%) of the TED/TED arm achieved sustained clinical response, alongside 16 of 29 (55%) of the PBO/TED arm — durability of effect over chronic dosing was the dominant long-term-safety question STEPS-2 addressed, and the response held. The pediatric Phase III is Kocoshis SA, Merritt RJ, Hill S et al., J Parenter Enteral Nutr 2020, 44:621–631 — a 24-week trial randomizing 59 SBS-intestinal-failure pediatric patients to teduglutide 0.025 mg/kg/day, 0.05 mg/kg/day, or non-blinded standard of care, with the primary endpoint (≥20% PS reduction) met by 54.2%, 69.2%, and 11.1% of the three groups respectively. The pediatric STEPS data anchored the 2019 FDA pediatric label extension, an unusual regulatory completeness for a peptide indication — most peptide approvals exclude pediatric populations entirely.

The trajectory that produced the 2012 FDA approval and the 2019 pediatric extension is what makes teduglutide the reference comparator any peptide-development conversation about gastrointestinal indications returns to. The same trajectory is referenced in the IBD and peptides dossier — teduglutide is not approved for ulcerative colitis or Crohn's disease, and the SBS population is structurally distinct from active inflammatory disease, but the existence of a successful Phase III program for a GI-targeted peptide is the proof of concept that the field's BPC-157 and KPV development arcs have not yet replicated. The honest framing is precise: the molecule's regulatory record is in SBS, not IBD; the trajectory demonstrates that GI peptide pharmacology can survive rigorous development if the indication is well-defined, the mechanism is well-characterized, and a sponsor sees the program through.

The off-label IBD interest the biohacker community periodically circles back to deserves direct framing. The most informative single trial is Buchman AL, Katz S, Fang JC et al., Inflamm Bowel Dis 2010, 16:962–973 — a Phase II pilot study that randomized 100 patients with moderate-to-severe Crohn's disease 1:1:1:1 to placebo or teduglutide 0.05, 0.10, or 0.20 mg/kg daily for 8 weeks. Numerically higher CDAI response and remission rates were observed across all three teduglutide doses; the highest-dose (0.2 mg/kg) arm reached 44% response and 32% remission versus 32% and 20% on placebo. The signal was directionally favorable but the trial was not powered for definitive efficacy, and no successor sponsor advanced teduglutide to a Phase III Crohn's program. The 2024 retrospective single-center series Siu RK, Karime C, Hashash JG et al., Crohns Colitis 360 2024, 6:otae007 followed 32 patients with Crohn's-etiology SBS on teduglutide; 26 of 32 (81%) met the ≥20% parenteral support reduction endpoint, with no signal that underlying Crohn's biology undermined the mucosal-growth response — informative about the mechanism's robustness across etiologies, but not a controlled trial of teduglutide as IBD remission therapy. Outside SBS-with-comorbid-Crohn's, no published Phase III randomized trial has tested teduglutide as monotherapy or adjunctive therapy for IBD induction or maintenance.

The access economics are also unusual for the practitioner peptide conversation. Teduglutide is distributed exclusively through specialty pharmacy channels, with historical list price disclosed at approximately $295,000 per patient per year (dissected at first launch by BioCentury) and contemporary modeling describing real-world annual costs north of $400,000. Most adult SBS patients access the drug through orphan-drug insurance pathways and copay-assistance programs rather than out-of-pocket purchase. The gray-market compounded supply chains that surround BPC-157, KPV, TB-500, and the broader research-chemical peptide landscape are largely absent here — the SBS patient population is small, the medical-supervision requirement is unusually high (polyp surveillance, fluid-balance monitoring, parenteral-support taper), and the pharmacology rewards close clinical follow-up rather than self-experimentation.